Compare IDEXX Laboratories, Inc. (IDXX) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares MSCI China ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares MSCI China ETF trades at $52.55 (market cap $5.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.8× iShares MSCI China ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,575,471). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares MSCI China ETF for 63 Days on average.
| IDXX | MCHI | |
|---|---|---|
Market Cap | $40.43B | $5.94B |
Volume | 692,164 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $65.59 |
52-Week Low | $504.70 | $50.48 |
Typical Hold Time | 46 Days | 63 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
MCHI trades at $51.36, down 0.54% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights trade tensions ahead of U.S.-China talks, though corporate profits surged 26% in Q2. Technical indicators show oversold conditions with RSI at 25.44 suggesting potential for near-term bounce.
The outlook remains cautious given China's macroeconomic pressures and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations versus U.S. indices. Key risks include potential export controls, protectionism threats, and China's reliance on infrastructure spending rather than broad stimulus to support growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
